Pioneering the development
of engineered IgM antibodies
for the treatment of cancer

antibody-solo

Agonist and Bispecific IgM: Nature’s Approach to Highly Avid, Multivalent Antibodies

November, 2019 – PEGS Europe, Lisbon Bruce Keyt, PhD, Chief Scientific Officer IGM Biosciences, Inc.,…

Read More...

A New Era in Cancer Therapeutics: Biologic Problems and Engineering Solutions

November, 2019 – PEGS Europe, Lisbon Daniel Chen, MD, PhD, Chief Medical Officer IGM Biosciences,…

Read More...

IGM Biosciences to Present at Three Upcoming Investor Conferences

MOUNTAIN VIEW, Calif. — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on…

Read More...

IGM Biosciences Announces Third Quarter 2019 Financial Results

MOUNTAIN VIEW, Calif.,  — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on…

Read More...

IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin’s Lymphoma

MOUNTAIN VIEW, Calif., Oct. 02, 2019 — IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company focused on…

Read More...

IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

MOUNTAIN VIEW, Calif., Sept. 20, 2019 — IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the…

Read More...